With efficacy data in hand, Gilead wants to balance economic sustainability with broad availability of remdesivir for COVID-19 patients. The firm did not alter guidance on Q1 earnings call.
One day after two trials indicated remdesivir offers therapeutic benefit in patients hospitalized for COVID-19 infections, Gilead Sciences Inc.’s first quarter earnings call was dominated by discussion of the antiviral, including how the company might build a commercial business for treating the novel coronavirus.
Gilead did not update its revenue guidance for 2020 on the 30 April call, and said it saw roughly $200m...
Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.
Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.
Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?
